The European Commission has notified Lundbeck that it has opened proceedings against the company. The purpose is to identify whether Lundbeck has misused a dominant position or has been involved in anticompetitive agreements in the markets for citalopram.
Lundbeck has said that it is co-operating fully with the European Commission. The company is confident that it has complied with all relevant national and EU competition legislation.
The Commission will investigate potential breaches by the company of the EU rules on restrictive business practices and abuse of a dominant market position. Particularly, it intends to investigate unilateral behaviour and agreements by Lundbeck related to delays in entry of generic versions of its antidepressant Celexa/Cipramil (citalopram) into European Economic Area (EEA) markets, reported pharmatimes.